Researchers conducted a retrospective cohort study of patients undergoing TAVR at 229 U.S. sites between November 2011 and September 2014. They used the Society of Thoracic Surgeons/American College of Cardiology TVT Registry and the CMS database.
Here are four findings:
1. Permanent pacemaker placement was required within 30 days of TAVR in 651 of the 9,785 patients (6.7 percent).
2. Age, prior conduction defect and use of self-expanding valve were positive predictors of pacemaker implantation.
3. Permanent pacemaker implantation was associated with a seven-day median hospital stay and 56.7-hour intensive care unit stay.
4. Permanent pacemaker implantation was also associated with a 24.1 percent mortality rate.
More articles on healthcare quality:
ECRI names 10 health technology hazards for 2017 — infusion errors, scope cleaning top list
HHS report identifies 7 new cancer-causing substances
AFM ruled out in death of Seattle Children’s patient, confirmed in 8 others
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
